Healthcare Industry News: Elan
News Release - June 9, 2014
Rubicon Genomics Adds European Distributors Ahead Of New Product LaunchesRubicon Is Expanding Worldwide Distribution Channels for Its Growing Line of DNA Library Prep Kits In Advance of Upcoming New Product Launches
ANN ARBOR, Mich., June 9, 2014 -- (Healthcare Sales & Marketing Network) -- Rubicon Genomics, Inc., today announced that it signed agreements with seven distributors in Europe to expand the availability of its leading DNA library preparation products, including ThruPLEX®-FD Prep Kit and PicoPLEX™ DNA-seq Kit for use with Illumina® next-generation sequencing (NGS) systems and PicoPLEX™ WGA Kit for use on arrays, and to prepare for new product launches planned for the coming months. The new distributors include Cambridge Bioscience in the UK and IrEland, Biozym Scientific GmbH in Germany and Austria, AB ANALITICA in Italy, Sopachem in the Benelux countries, Nordic Biolabs in Denmark and Sweden, Immuno Diagnostic Oy in Finland and YBUX in Romania, the Slovak Republic and the Czech Republic.
James Koziarz, PhD, CEO of Rubicon Genomics, commented, "Our healthy increase in revenues during the past year reflects the early stages of our strategic efforts to aggressively expand our product offerings and build a network of first-rate distributors around the globe. Now that we have our key distribution channels in place, we expect to achieve even greater sales growth going forward, through broader distribution of our recently launched products and the addition of product enhancements in the coming months."
During the second quarter, Rubicon will launch ThruPLEX DNA-seq 48D kits and ThruPLEX DNA-seq 96D kits. These enhancements of the company's ThruPLEX FD Prep kits DNA-seq product line offer an increased number of barcodes, which will enable scientists to use ThruPLEX DNA-seq kits for high throughput applications, and reformulated chemistries that provide improved performance. These kits are currently undergoing Beta testing worldwide with samples ranging from cell-free (cf) plasma DNA to human oocyte cDNA, and initial response has been excellent.
The enhanced ThruPLEX DNA-seq products address the needs of clinicians and scientists working in high throughput applications by adding either 48 or 96 dual barcodes to the kit. The chemistry has also been reformulated and demonstrates improved performance that is especially helpful for challenging clinical specimens, such as plasma or FFPE samples, where DNA input amounts are typically low and/or damaged.
ThruPLEX DNA-seq kits streamline library preparation for DNA/cDNA and reduce sample input amounts to picogram levels. The ThruPLEX DNA-seq kit's patented technology delivers a highly-efficient and user-friendly three-step process that takes place in a single tube in less than two hours, eliminating purifications and speeding time to results. ThruPLEX DNA-seq provides accurate and reproducible results for a variety of applications.
About Rubicon Genomics
Rubicon Genomics, Inc. is a leader in the development and commercialization of innovative sample-specific nucleic acid library preparation products used in research and clinical testing on NGS, microarray and q-PCR platforms. The company creates efficient molecular biology tools for genetic, epigenetic and expression analysis of difficult samples to facilitate gene-based research, drug development and diagnostics. Privately-held Rubicon is located in Ann Arbor, Michigan. For more information, visit rubicongenomics.com.
Source: Rubicon Genomics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.